{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:02:33Z","timestamp":1794049353812,"version":"4.8.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA214254"],"award-info":[{"award-number":["U01CA214254"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA214254"],"award-info":[{"award-number":["U01CA214254"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA214254"],"award-info":[{"award-number":["U01CA214254"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001109","name":"Flinn Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001109","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Dorrance Family Fund"},{"name":"HonorHealth Foundation"},{"name":"the Dorrance Family Fund, the Marley Foundation, the Seena Magowitz Foundation, Purple Pansies, John E. Sabga Foundation, the TGen Pancreatic Cancer National Advisory Council"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,11,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lack of reliable biomarkers for early detection and monitoring contributes to the poor prognosis of pancreatic ductal adenocarcinoma (PDAC), as the current clinical marker, CA19-9, lacks adequate specificity and sensitivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Serum concentrations of ALPPL2-positive and THBS2-positive exosomes were measured using an ExoView assay in two cohorts: a cohort of 219 subjects, including non-disease controls and patients with early- or late-stage PDAC, and a longitudinal cohort of 26 patients with advanced PDAC undergoing treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Exosomal ALPPL2 and THBS2 distinguished non-cancer cases from PDAC with high accuracy; area under the curve (AUC) values\u2009=\u20090.983, 0.993, and 0.983 for ALPPL2, THBS2, and the dual marker combination, respectively. Additionally, changes in the concentrations of ALPPL2\n                      <jats:sup>+<\/jats:sup>\n                      and THBS2\n                      <jats:sup>+<\/jats:sup>\n                      exosomes strongly correlated with radiographic tumor size changes during treatment in both CA19-9-elevated (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.016 and 0.014 for ALPPL2 and THBS2, respectively) and non-elevated patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003 and 0.006 for ALPPL2 and THBS2, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Serum exosomal ALPPL2 and THBS2 can accurately discriminate patients with PDAC from individuals with non-cancerous conditions and healthy controls. Changes in serum exosomal ALPPL2 and THBS2 levels significantly correlate with patients\u2019 response to treatment in both CA19-9-elevated and non-elevated patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-025-03167-2","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T02:01:48Z","timestamp":1756864908000},"page":"1335-1343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma"],"prefix":"10.1038","volume":"133","author":[{"given":"Kuntal","family":"Halder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkut H.","family":"Borazanci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayle S.","family":"Jameson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Vrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Cridebring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Aldakkak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruyoshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuro","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1396-6341","authenticated-orcid":false,"given":"Ajay","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4723-7681","authenticated-orcid":false,"given":"Daniel D.","family":"Von Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9031-9880","authenticated-orcid":false,"given":"Haiyong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"3167_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3167_CR2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1470-2045(23)00516-8","volume":"25","author":"B Gyawali","year":"2024","unstructured":"Gyawali B, Booth CM. Treatment of metastatic pancreatic cancer: 25 years of innovation with little progress for patients. Lancet Oncol. 2024;25:167\u201370.","journal-title":"Lancet Oncol"},{"key":"3167_CR3","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s13046-024-03166-w","volume":"43","author":"KL Reese","year":"2024","unstructured":"Reese KL, Pantel K, Smit DJ. Multibiomarker panels in liquid biopsy for early detection of pancreatic cancer - a comprehensive review. J Exp Clin Cancer Res. 2024;43:250.","journal-title":"J Exp Clin Cancer Res"},{"key":"3167_CR4","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1053\/j.gastro.2019.01.259","volume":"156","author":"AD Singhi","year":"2019","unstructured":"Singhi AD, Koay EJ, Chari ST, Maitra A. Early detection of pancreatic cancer: opportunities and challenges. Gastroenterology. 2019;156:2024\u201340.","journal-title":"Gastroenterology"},{"key":"3167_CR5","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1097\/MPA.0000000000001133","volume":"47","author":"A Kardosh","year":"2018","unstructured":"Kardosh A, Lichtensztajn DY, Gubens MA, Kunz PL, Fisher GA, Clarke CA. Long-term survivors of pancreatic cancer: a california population-based study. Pancreas. 2018;47:958\u201366.","journal-title":"Pancreas"},{"key":"3167_CR6","volume":"10","author":"A Bengtsson","year":"2020","unstructured":"Bengtsson A, Andersson R, Ansari D. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. Sci Rep. 2020;10:16425.","journal-title":"Sci Rep"},{"key":"3167_CR7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/SLA.0000000000002957","volume":"268","author":"S Tsai","year":"2018","unstructured":"Tsai S, Christians KK, George B, Ritch PS, Dua K, Khan A, et al. A phase II clinical trial of molecular profiled neoadjuvant therapy for localized pancreatic ductal adenocarcinoma. Ann Surg. 2018;268:610\u20139.","journal-title":"Ann Surg"},{"key":"3167_CR8","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/cac2.12204","volume":"41","author":"J Yang","year":"2021","unstructured":"Yang J, Xu R, Wang C, Qiu J, Ren B, You L. Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review. Cancer Commun. 2021;41:1257\u201374.","journal-title":"Cancer Commun"},{"key":"3167_CR9","first-page":"105","volume":"3","author":"UK Ballehaninna","year":"2012","unstructured":"Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol. 2012;3:105\u201319.","journal-title":"J Gastrointest Oncol"},{"key":"3167_CR10","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdr561","volume":"23","author":"JL Humphris","year":"2012","unstructured":"Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 2012;23:1713\u201322.","journal-title":"Ann Oncol"},{"key":"3167_CR11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102719","volume":"125","author":"E Brozos-Vazquez","year":"2024","unstructured":"Brozos-Vazquez E, Toledano-Fonseca M, Costa-Fraga N, Garcia-Ortiz MV, Diaz-Lagares A, Rodriguez-Ariza A, et al. Pancreatic cancer biomarkers: a pathway to advance in personalized treatment selection. Cancer Treat Rev. 2024;125:102719.","journal-title":"Cancer Treat Rev"},{"key":"3167_CR12","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217245","volume":"604","author":"B Haab","year":"2024","unstructured":"Haab B, Qian L, Staal B, Jain M, Fahrmann J, Worthington C, et al. A rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 alone. Cancer Lett. 2024;604:217245.","journal-title":"Cancer Lett"},{"key":"3167_CR13","doi-asserted-by":"crossref","DOI":"10.1177\/11795549231215966","volume":"18","author":"Q Maqsood","year":"2024","unstructured":"Maqsood Q, Sumrin A, Saleem Y, Wajid A, Mahnoor M. Exosomes in cancer: diagnostic and therapeutic applications. Clin Med Insights Oncol. 2024;18:11795549231215966.","journal-title":"Clin Med Insights Oncol"},{"key":"3167_CR14","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccell.2016.10.009","volume":"30","author":"A Becker","year":"2016","unstructured":"Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell. 2016;30:836\u201348.","journal-title":"Cancer Cell"},{"key":"3167_CR15","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cell.2020.07.009","volume":"182","author":"A Hoshino","year":"2020","unstructured":"Hoshino A, Kim HS, Bojmar L, Gyan KE, Cioffi M, Hernandez J, et al. Extracellular vesicle and particle biomarkers define multiple human cancers. Cell. 2020;182:1044\u201361.e18.","journal-title":"Cell"},{"key":"3167_CR16","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ncb3169","volume":"17","author":"B Costa-Silva","year":"2015","unstructured":"Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 2015;17:816\u201326.","journal-title":"Nat Cell Biol"},{"key":"3167_CR17","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1053\/j.gastro.2022.06.090","volume":"163","author":"K Nakamura","year":"2022","unstructured":"Nakamura K, Zhu Z, Roy S, Jun E, Han H, Munoz RM, et al. An exosome-based transcriptomic signature for noninvasive, early detection of patients with pancreatic ductal adenocarcinoma: a multicenter cohort study. Gastroenterology. 2022;163:1252\u201366.e2.","journal-title":"Gastroenterology"},{"key":"3167_CR18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3892\/or.2024.8846","volume":"53","author":"X Luan","year":"2025","unstructured":"Luan X, Wang X, Bian G, Li X, Gao Z, Liu Z, et al. Exosome applications for the diagnosis and treatment of pancreatic ductal adenocarcinoma: an update (Review). Oncol Rep. 2025;53:13.","journal-title":"Oncol Rep"},{"key":"3167_CR19","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202000011","volume":"353","author":"DM Zaher","year":"2020","unstructured":"Zaher DM, El-Gamal MI, Omar HA, Aljareh SN, Al-Shamma SA, Ali AJ, et al. Recent advances with alkaline phosphatase isoenzymes and their inhibitors. Arch Pharm. 2020;353:e2000011.","journal-title":"Arch Pharm"},{"key":"3167_CR20","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1158\/0008-5472.CAN-20-1418","volume":"80","author":"Y Su","year":"2020","unstructured":"Su Y, Zhang X, Bidlingmaier S, Behrens CR, Lee NK, Liu B. ALPPL2 is a highly specific and targetable tumor cell surface antigen. Cancer Res. 2020;80:4552\u201364.","journal-title":"Cancer Res"},{"key":"3167_CR21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF00302465","volume":"18","author":"K Koshida","year":"1990","unstructured":"Koshida K, Wahren B. Placental-like alkaline phosphatase in seminoma. Urol Res. 1990;18:87\u201392.","journal-title":"Urol Res"},{"key":"3167_CR22","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3233\/CBM-160665","volume":"17","author":"M Orsaria","year":"2016","unstructured":"Orsaria M, Londero AP, Marzinotto S, Di Loreto C, Marchesoni D, Mariuzzi L. Placental type alkaline phosphatase tissue expression in ovarian serous carcinoma. Cancer Biomark. 2016;17:479\u201386.","journal-title":"Cancer Biomark"},{"key":"3167_CR23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.humpath.2018.11.019","volume":"86","author":"S Liu","year":"2019","unstructured":"Liu S, Mao Q, Xue W, Zhang X, Qi Y, Wang Y, et al. High expression of ALPPL2 is associated with poor prognosis in gastric cancer. Hum Pathol. 2019;86:49\u201356.","journal-title":"Hum Pathol"},{"key":"3167_CR24","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1158\/0008-5472.CAN-12-3682","volume":"73","author":"P Dua","year":"2013","unstructured":"Dua P, Kang HS, Hong SM, Tsao MS, Kim S, Lee DK. Alkaline phosphatase ALPPL-2 is a novel pancreatic carcinoma-associated protein. Cancer Res. 2013;73:1934\u201345.","journal-title":"Cancer Res"},{"key":"3167_CR25","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-022-02622-x","volume":"22","author":"X Liao","year":"2022","unstructured":"Liao X, Wang W, Yu B, Tan S. Thrombospondin-2 acts as a bridge between tumor extracellular matrix and immune infiltration in pancreatic and stomach adenocarcinomas: an integrative pan-cancer analysis. Cancer Cell Int. 2022;22:213.","journal-title":"Cancer Cell Int"},{"key":"3167_CR26","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1634\/theoncologist.2019-0680","volume":"25","author":"TYS Le Large","year":"2020","unstructured":"Le Large TYS, Meijer LL, Paleckyte R, Boyd LNC, Kok B, Wurdinger T, et al. Combined expression of plasma thrombospondin-2 and CA19-9 for diagnosis of pancreatic cancer and distal cholangiocarcinoma: a proteome approach. Oncologist. 2020;25:e634\u2013e43.","journal-title":"Oncologist"},{"key":"3167_CR27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1158\/1940-6207.CAPR-20-0403","volume":"14","author":"S Udgata","year":"2021","unstructured":"Udgata S, Takenaka N, Bamlet WR, Oberg AL, Yee SS, Carpenter EL, et al. THBS2\/CA19-9 detecting pancreatic ductal adenocarcinoma at diagnosis underperforms in prediagnostic detection: implications for biomarker advancement. Cancer Prev Res. 2021;14:223\u201332.","journal-title":"Cancer Prev Res"},{"key":"3167_CR28","doi-asserted-by":"crossref","DOI":"10.1038\/s41389-020-00285-9","volume":"9","author":"P Noel","year":"2020","unstructured":"Noel P, Hussein S, Ng S, Antal CE, Lin W, Rodela E, et al. Triptolide targets super-enhancer networks in pancreatic cancer cells and cancer-associated fibroblasts. Oncogenesis. 2020;9:100.","journal-title":"Oncogenesis"},{"key":"3167_CR29","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671\u20135.","journal-title":"Nat Methods"},{"key":"3167_CR30","volume":"9","author":"J Chen","year":"2021","unstructured":"Chen J, Li P, Zhang T, Xu Z, Huang X, Wang R, et al. Review on strategies and technologies for exosome isolation and purification. Front Bioeng Biotechnol. 2021;9:811971.","journal-title":"Front Bioeng Biotechnol"},{"key":"3167_CR31","doi-asserted-by":"crossref","first-page":"8544","DOI":"10.3390\/ijms23158544","volume":"23","author":"K Breitwieser","year":"2022","unstructured":"Breitwieser K, Koch LF, Tertel T, Proestler E, Burgers LD, Lipps C, et al. Detailed characterization of small extracellular vesicles from different cell types based on tetraspanin composition by ExoView R100 platform. Int J Mol Sci. 2022;23:8544.","journal-title":"Int J Mol Sci"},{"key":"3167_CR32","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.omtm.2019.08.016","volume":"15","author":"HS Shin","year":"2019","unstructured":"Shin HS, Jung SB, Park S, Dua P, Lee DK. ALPPL2 is a potential diagnostic biomarker for pancreatic cancer-derived extracellular vesicles. Mol Ther Methods Clin Dev. 2019;15:204\u201310.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"3167_CR33","volume":"32","author":"S Lei","year":"2022","unstructured":"Lei S, Chen X, Gao Y, Shuai M, Zhou W, Li J, et al. ALPPL2-binding peptide facilitates targeted mRNA delivery for efficient hepatocellular carcinoma gene therapy. Adv Funct Mater. 2022;32:2204342.","journal-title":"Adv Funct Mater"},{"key":"3167_CR34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd8836","volume":"13","author":"A Hyrenius-Wittsten","year":"2021","unstructured":"Hyrenius-Wittsten A, Su Y, Park M, Garcia JM, Alavi J, Perry N, et al. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci Transl Med. 2021;13:eabd8836.","journal-title":"Sci Transl Med"},{"key":"3167_CR35","doi-asserted-by":"crossref","first-page":"TPS3159","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3159","volume":"40","author":"NJ Lakhani","year":"2022","unstructured":"Lakhani NJ, F CF, Perez CA, Wehr A, McGoldrick SM, LoRusso P. Phase 1 study of SGN-ALPV, a novel, investigational vedotin antibody\u2013drug conjugate directed to ALPP\/ALPPL2 in advanced solid tumors (SGNALPV-001, trial in progress). J Clin Oncol. 2022;40:TPS3159.","journal-title":"J Clin Oncol"},{"key":"3167_CR36","first-page":"717","volume":"23","author":"M Basiri","year":"2021","unstructured":"Basiri M, Pahlavanneshan S. Evaluation of placental alkaline phosphatase expression as a potential target of solid tumors immunotherapy by using gene and protein expression repositories. Cell J. 2021;23:717\u201321.","journal-title":"Cell J"},{"key":"3167_CR37","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1158\/1538-7445.AM2024-3137","volume":"84","author":"BK Yeung","year":"2024","unstructured":"Yeung BK, Koh XH, Ling WL, Tan W, Wu YX, Zhang XY, et al. Development of AT2604, a highly efficacious ADC targeting alkaline phosphatases ALPP and ALPPL2. Cancer Res. 2024;84:3137.","journal-title":"Cancer Res"},{"key":"3167_CR38","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.7150\/thno.29247","volume":"9","author":"AW Berger","year":"2019","unstructured":"Berger AW, Schwerdel D, Reinacher-Schick A, Uhl W, Algul H, Friess H, et al. A blood-based multi marker assay supports the differential diagnosis of early-stage pancreatic cancer. Theranostics. 2019;9:1280\u20137.","journal-title":"Theranostics"},{"key":"3167_CR39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s12094-021-02685-8","volume":"24","author":"J Byrling","year":"2022","unstructured":"Byrling J, Hilmersson KS, Ansari D, Andersson R, Andersson B. Thrombospondin-2 as a diagnostic biomarker for distal cholangiocarcinoma and pancreatic ductal adenocarcinoma. Clin Transl Oncol. 2022;24:297\u2013304.","journal-title":"Clin Transl Oncol"},{"key":"3167_CR40","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.amjsurg.2018.08.026","volume":"217","author":"RE Simpson","year":"2019","unstructured":"Simpson RE, Yip-Schneider MT, Wu H, Fan H, Liu Z, Korc M, et al. Circulating Thrombospondin-2 enhances prediction of malignant intraductal papillary mucinous neoplasm. Am J Surg. 2019;217:425\u20138.","journal-title":"Am J Surg"},{"key":"3167_CR41","volume":"9","author":"J Kim","year":"2017","unstructured":"Kim J, Bamlet WR, Oberg AL, Chaffee KG, Donahue G, Cao XJ, et al. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. Sci Transl Med. 2017;9:eaah5583.","journal-title":"Sci Transl Med"},{"key":"3167_CR42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canlet.2021.12.025","volume":"528","author":"P Nan","year":"2022","unstructured":"Nan P, Dong X, Bai X, Lu H, Liu F, Sun Y, et al. Tumor-stroma TGF-beta1-THBS2 feedback circuit drives pancreatic ductal adenocarcinoma progression via integrin alpha(v)beta(3)\/CD36-mediated activation of the MAPK pathway. Cancer Lett. 2022;528:59\u201375.","journal-title":"Cancer Lett"},{"key":"3167_CR43","volume":"11","author":"B George","year":"2021","unstructured":"George B, Kent M, Surinach A, Lamarre N, Cockrum P. The association of real-world CA 19-9 level monitoring patterns and clinical outcomes among patients with metastatic pancreatic ductal adenocarcinoma. Front Oncol. 2021;11:754687.","journal-title":"Front Oncol"},{"key":"3167_CR44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fonc.2013.00155","volume":"3","author":"U Pelzer","year":"2013","unstructured":"Pelzer U, Hilbig A, Sinn M, Stieler J, Bahra M, Dorken B, et al. Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy. Front Oncol. 2013;3:155.","journal-title":"Front Oncol"},{"key":"3167_CR45","first-page":"340","volume":"13","author":"KE Poruk","year":"2013","unstructured":"Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL, et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med. 2013;13:340\u201351.","journal-title":"Curr Mol Med"},{"key":"3167_CR46","doi-asserted-by":"crossref","first-page":"630","DOI":"10.5306\/wjco.v13.i7.630","volume":"13","author":"DV Balaban","year":"2022","unstructured":"Balaban DV, Marin FS, Manucu G, Zoican A, Ciochina M, Mina V, et al. Clinical characteristics and outcomes in carbohydrate antigen 19-9 negative pancreatic cancer. World J Clin Oncol. 2022;13:630\u201340.","journal-title":"World J Clin Oncol"},{"key":"3167_CR47","doi-asserted-by":"crossref","unstructured":"Dang DK, Park BH. Circulating tumor DNA: current challenges for clinical utility. J Clin Invest. 2022;132:e154941.","DOI":"10.1172\/JCI154941"},{"key":"3167_CR48","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pan.2020.12.017","volume":"21","author":"L Sivapalan","year":"2021","unstructured":"Sivapalan L, Kocher HM, Ross-Adams H, Chelala C. Molecular profiling of ctDNA in pancreatic cancer: Opportunities and challenges for clinical application. Pancreatology. 2021;21:363\u201378.","journal-title":"Pancreatology"},{"key":"3167_CR49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","volume":"22","author":"K Pantel","year":"2025","unstructured":"Pantel K, Alix-Panabieres C. Minimal residual disease as a target for liquid biopsy in patients with solid tumours. Nat Rev Clin Oncol. 2025;22:65\u201377.","journal-title":"Nat Rev Clin Oncol"},{"key":"3167_CR50","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jmoldx.2024.07.001","volume":"26","author":"EM Alexander","year":"2024","unstructured":"Alexander EM, Miller HA, Egger ME, Smith ML, Yaddanapudi K, Linder MW. The correlation between plasma circulating tumor DNA and radiographic tumor burden. J Mol Diagn. 2024;26:952\u201361.","journal-title":"J Mol Diagn"},{"key":"3167_CR51","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/jnci\/93.14.1054","volume":"93","author":"MS Pepe","year":"2001","unstructured":"Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93:1054\u201361.","journal-title":"J Natl Cancer Inst"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03167-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03167-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03167-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T21:46:16Z","timestamp":1761774376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03167-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,11,16]]}},"alternative-id":["3167"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03167-2","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HH is a SAB member of Stromatis Pharma and a consultant for ImproveBio. He also receives research funding from Avicenna Biosciences, Exact Therapeutics, and Minneamrita Therapeutics. DVH has stock and other ownership interests in Medtronic, CerRx, SynRevRx, United Healthcare, Anthem Inc., Stromatis Pharma, Systems Oncology, Stingray Therapeutics, Orpheus Bioscience, AADi, Origin Commercial Advisors, Halia Therapeutics, Lycia Therapeutics, (3\u2009+\u20092) Pharma, AcuViz; Consulting or advisory role at\u00a0ImagingEndpoints, CanBas, Lixte Biotechnology, TD2, Phosplatin Therapeutics, SOTIO, Immunophotonics, Oncology Venture, Novita Pharmaceuticals, Vicus Therapeutics, AiMed, Erimos Pharmaceuticals, Pfizer, ImmuneOncia, Viracta Pharmaceuticals, AlaMab Therapeutics, Xerient, Lycia Therapeutics, EXACT Therapeutics, ImaginAb, Signablok, Compass Therapeutics, Sellas Life Sciences, Catamaran Bio, SMP Oncology fka SDP\/Tolero, Red Arrow Therapeutics, Soley Therapeutics, Invios GmbH, Mekanistic Therapeutics, POINT Biopharma, Remunity, SIWA Therapeutics, Xenthera, Indaptus fka Decoy, Panavance Therapeutics fka Feistlich, CyMon Bio, Bryologyx, Moleculin Biotech, EnGeneIC, Race Oncology, Autonomix, Econic Biosciences, Crinetics Pharmaceuticals, Diakonos Research, Improve Bio, Duo Oncology, ImmuVia, WUGEN, Inc., and Origin Commercial Advisors. Research funding from Lilly, Genentech, Celgene, Incyte, Merrimack, Plexxikon, Minneamrita Therapeutics, Abbvie, Aduro Biotech, Cleave Bioscience, CytRx Corporation, Daiichi Sankyo, Deciphera, Endocyte, Exelixis, Five Prime Therapeutics, Gilead Sciences, Merck, Pfizer, Pharmacyclics, Phoenix Biotech, Samumed, Strategia, and Halozyme. The rest of the authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The collection of blood samples and clinical data used in this study was performed in accordance with the Declaration of Helsinki and was approved by the Institutional Review Boards (IRBs) of Translational Genomics Research Institute (WCG IRB), City of Hope (City of Hope IRB), HonorHealth Research Institute (HonorHealth IRB), Medical College of Wisconsin (MCW IRB), and Nagoya University School of Medicine (Nagoya University IRB). Consent was obtained from each participating subject.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}